Haematologica (Dec 2024)
Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms
- Jayastu Senapati,
- Sanam Loghavi,
- Guillermo Garcia-Manero,
- Guillin Tang,
- Tapan Kadia,
- Nicholas J. Short,
- Hussein A. Abbas,
- Naszrin Arani,
- Courtney D. DiNardo,
- Gautam Borthakur,
- Naveen Pemmaraju,
- Betul Oran,
- Elizabeth Shpall,
- Uday Popat,
- Richard Champlin,
- Sherry Pierce,
- Sankalp Arora,
- Ghayas Issa,
- Musa Yilmaz,
- Keyur Patel,
- Koichi Takahashi,
- Guillermo Montalban-Bravo,
- Danielle Hammond,
- Fadi G. Haddad,
- Farhad Ravandi,
- Hagop M. Kantarjian,
- Naval G. Daver
Affiliations
- Jayastu Senapati
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Sanam Loghavi
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
- Guillermo Garcia-Manero
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Guillin Tang
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
- Tapan Kadia
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Nicholas J. Short
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Hussein A. Abbas
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Naszrin Arani
- Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
- Courtney D. DiNardo
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Gautam Borthakur
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Naveen Pemmaraju
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Betul Oran
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
- Elizabeth Shpall
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
- Uday Popat
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
- Richard Champlin
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
- Sherry Pierce
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Sankalp Arora
- Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
- Ghayas Issa
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Musa Yilmaz
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Keyur Patel
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Koichi Takahashi
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Guillermo Montalban-Bravo
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Danielle Hammond
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Fadi G. Haddad
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Farhad Ravandi
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Hagop M. Kantarjian
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Naval G. Daver
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- DOI
- https://doi.org/10.3324/haematol.2024.286465
- Journal volume & issue
-
Vol. 999,
no. 1
Abstract
In myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 aberrations, dissecting the interaction amongst patient, disease and treatment factors are important for therapeutic decisions and prognostication. This retrospective analysis included patients with newly diagnosed MDS (>5% blasts) and AML with TP53 mutation(s) treated at MD Anderson Cancer Center. We factored patient age, TP53 aberration burden, therapy intensity and use of venetoclax in the AML subgroup, and allogeneic hematopoietic stem cell transplantation (HSCT) to interrogate outcomes. TP53 was annotated as high-risk (TP53HR) if >1 mutation, one mutation + allelic deletion or a single mutation with variant allele frequency (VAF) ≥40%; TP53 low risk (TP53LR) included a single TP53 mutation VAF
